These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33688084)

  • 1. Effects of modified risk tobacco product claims on consumer comprehension and risk perceptions of IQOS.
    Yang B; Massey ZB; Popova L
    Tob Control; 2022 Aug; 31(e1):e41-e49. PubMed ID: 33688084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IQOS labelling will mislead consumers.
    McKelvey K; Popova L; Kim M; Lempert LK; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s48-s54. PubMed ID: 30158208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of IQOS health warnings and modified risk claims among young adult cigarette smokers and non-smokers.
    Mays D; Johnson AC; Glasser A; Mercincavage M; Strasser AA
    Tob Control; 2023 Jul; 32(4):505-508. PubMed ID: 34716283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Modified Risk Tobacco Product Claims on Consumer Responses.
    Seidenberg AB; Boynton MH; Brewer NT; Lazard AJ; Sheeran P; Ribisl KM
    Nicotine Tob Res; 2024 Mar; 26(4):435-443. PubMed ID: 37791605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of FDA endorsement and modified risk versus exposure messaging in IQOS ads: a randomised factorial experiment among US and Israeli adults.
    Berg CJ; Duan Z; Wang Y; Thrasher JF; Bar-Zeev Y; Abroms LC; Romm KF; Khayat A; Levine H
    Tob Control; 2024 Mar; 33(e1):e69-e77. PubMed ID: 36428095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Organic," "Natural," and "Additive-Free" Cigarettes: Comparing the Effects of Advertising Claims and Disclaimers on Perceptions of Harm.
    Baig SA; Byron MJ; Lazard AJ; Brewer NT
    Nicotine Tob Res; 2019 Jun; 21(7):933-939. PubMed ID: 29529277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PMI's heated tobacco products marketing claims of reduced risk and reduced exposure may entice youth to try and continue using these products.
    McKelvey K; Baiocchi M; Halpern-Felsher B
    Tob Control; 2020 Dec; 29(e1):e18-e24. PubMed ID: 32029537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of advertising features on smokers' and non-smokers' perceptions of a reduced nicotine cigarette modified risk tobacco product.
    Mercincavage M; Pacek LR; Thrasher J; Cappella JN; Delnevo C; Donny EC; Strasser AA
    Tob Control; 2023 Jan; 32(1):6-12. PubMed ID: 33858965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smokers' and Young Adult Non-Smokers' Perceptions and Perceived Impact of Snus and E-Cigarette Modified Risk Messages.
    Wackowski OA; Rashid M; Greene KL; Lewis MJ; O'Connor RJ
    Int J Environ Res Public Health; 2020 Sep; 17(18):. PubMed ID: 32961924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Young adults' attention to reduced exposure claims in IQOS advertising and associations with product perceptions and use intentions.
    Mercincavage M; Wackowski OA; Chen-Sankey J; Thrasher JF; Audrain-McGovern J; Strasser AA
    Nicotine Tob Res; 2024 Aug; ():. PubMed ID: 39109909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Communicating the relative health risks of E-cigarettes: An online experimental study exploring the effects of a comparative health message versus the EU nicotine addiction warnings on smokers' and non-smokers' risk perceptions and behavioural intentions.
    Kimber C; Frings D; Cox S; Albery IP; Dawkins L
    Addict Behav; 2020 Feb; 101():106177. PubMed ID: 31753541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure to IQOS ads and reduced exposure claims, and association with perceived risk from COVID-19 on IQOS purchase and use intentions: results from a web-based survey.
    Sharma A; Fix B; Hyland A; Bansal-Travers M; Quisenberry A; O'Connor R
    Front Public Health; 2023; 11():1307484. PubMed ID: 38269390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of IQOS risk perceptions on cigarette smoking behaviours: results from a prospective pilot study.
    DeAtley T; Stone MD; Strasser AA; Audrain-McGovern J
    Tob Control; 2024 Feb; 33(2):263-266. PubMed ID: 36002165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corporate communication of the relative health risks of IQOS through a webchat service.
    Braznell S; Branston JR; Gilmore AB
    Tob Control; 2023 Aug; 32(e2):e205-e211. PubMed ID: 35241501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing messages about comparative risk of electronic cigarettes and combusted cigarettes.
    Yang B; Owusu D; Popova L
    Tob Control; 2019 Jul; 28(4):440-448. PubMed ID: 30104408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in Biomarkers of Exposure on Switching From a Conventional Cigarette to Tobacco Heating Products: A Randomized, Controlled Study in Healthy Japanese Subjects.
    Gale N; McEwan M; Eldridge AC; Fearon IM; Sherwood N; Bowen E; McDermott S; Holmes E; Hedge A; Hossack S; Wakenshaw L; Glew J; Camacho OM; Errington G; McAughey J; Murphy J; Liu C; Proctor CJ
    Nicotine Tob Res; 2019 Aug; 21(9):1220-1227. PubMed ID: 29912406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perceived relative harm of heated tobacco products (IQOS), e-cigarettes, and cigarettes among adults in Canada: Findings from the ITC Project.
    Sutanto E; Miller CR; Smith DM; O'Connor RJ; Gravely S; Hammond D; Hyland A; Cummings KM; Quah ACK; Fong GT; Agar TK; Goniewicz ML
    Tob Induc Dis; 2020; 18():81. PubMed ID: 33013277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving IQOS packaging designs change perceptions of product appeal, uniqueness, quality and safety: a randomised experiment, 2018, USA.
    Lee JGL; Blanchflower TM; O'Brien KF; Averett PE; Cofie LE; Gregory KR
    Tob Control; 2019 Aug; 28(e1):e52-e55. PubMed ID: 31164489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IQOS Marketing in the US: The Need to Study the Impact of FDA Modified Exposure Authorization, Marketing Distribution Channels, and Potential Targeting of Consumers.
    Berg CJ; Abroms LC; Levine H; Romm KF; Khayat A; Wysota CN; Duan Z; Bar-Zeev Y
    Int J Environ Res Public Health; 2021 Oct; 18(19):. PubMed ID: 34639851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'The lesser devil you don't know': a qualitative study of smokers' responses to messages communicating comparative risk of electronic and combusted cigarettes.
    Owusu D; Lawley R; Yang B; Henderson K; Bethea B; LaRose C; Stallworth S; Popova L
    Tob Control; 2020 Mar; 29(2):217-223. PubMed ID: 31040224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.